U.S. Food and Drug Administration (FDA) approved idelalisib (Zydelig tablets, Gilead Sciences, Inc.) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. July 23, 2014. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm406410.htm
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
